Ilya Rachman
Vorstandsvorsitzender bei IMMIX BIOPHARMA, INC.
Vermögen: 2 Mio $ am 30.04.2024
Aktive Positionen von Ilya Rachman
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
IMMIX BIOPHARMA, INC. | Vorstandsvorsitzender | 01.01.2012 | - |
Vorsitzender | 01.01.2012 | - | |
Gründer | 01.01.2012 | - | |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Vorsitzender | - | - |
Karriereverlauf von Ilya Rachman
Ausbildung von Ilya Rachman
University of Illinois | Doctorate Degree |
University of Iowa | Undergraduate Degree |
University of California, Los Angeles | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 6 |
Operativ
Chairman | 2 |
Chief Executive Officer | 1 |
Founder | 1 |
Sektoral
Consumer Services | 4 |
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
IMMIX BIOPHARMA, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Health Technology |
- Börse
- Insiders
- Ilya Rachman
- Erfahrung